Journals / Online Türk Sağlık Bilimleri Dergisi / 2017 / Cilt: 2 - Sayı: 3

Cardivascular diseases of HIV/AIDS patients

HIV/AIDS Hastalarında Kalp ve Damar Hastalıkları

Pages
31–46
Publication Date
2017-09-30
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

In this article, the pathophysiology of cardiovascular diseases in AIDS patients will be summarized.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Heart diseases in AIDS patients are more frequent than in normal population.
📊
Key Findings & Data:Viral replication increases inflammation, and events triggered by inflammation increase cardiovascular disease.
💡
Conclusion & Impact:In this article, the pathophysiology of cardiovascular diseases in AIDS patients will be summarized.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:HIV · AIDS · Kalp ve damar hastalıkları

Abstract

Heart diseases in AIDS patients are more frequent than in normal population. Viral replication increases inflammation, and events triggered by inflammation increase cardiovascular disease. Although AIDS treatment reduces the incidence of cardiovascular disease in patients, the risk of cardiovascular disease continues. In this article, the pathophysiology of cardiovascular diseases in AIDS patients will be summarized.

Özet

AIDS hastalarında kalp ve damar hastalıkları normal topluma göre daha sıktır. Virüsün üremesi enflamasyonu arttırmakta, enflamasyonun tetiklediği olaylar da kalp ve damar hastalıkları arttırmaktadır. AIDS tedavisi hastalarda görülen kalp damar hastalıklarına sıklığını azaltsa da kardiyovasküler hastalık riski sürmektedir. Bu yazıda AIDS hastalarında ki kardiyovasküler hastalıklar özetlenmeye çalışılacaktır.

🔖

Cite This Article

KARABAY, O., KARABAY, M. (2017). Cardivascular diseases of HIV/AIDS patients. Online Türk Sağlık Bilimleri Dergisi, Cilt: 2 - Sayı: 3, 31–46. https://ajindex.com/articles/694544

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (8)

  1. Phillips AN, Neaton J, Lundgren JD. The role of HIV in serious diseases other than AIDS. AIDS 2008;22(18):2409–18.
  2. Hsue PY, Deeks SG, Hunt PW. Immunologic basis of cardiovascular disease in HIV-infected adults. J Infect Dis 2012;205 Suppl 3:S375–82. Triant VA, Lee H, Hadigan C, Grinspoon SK. Increased acute myocardial infarction rates and cardiovascular risk factors among patients with human immunodeficiency virus disease. J Clin Endocrinol Metab 2007;92(7):2506–12.
  3. Hansson GK. Inflammation, Atherosclerosis, and Coronary Artery Disease. N Engl J Med 2005;352(16):1685–95. Strategies for Management of Antiretroviral Therapy (SMART) Study Group, El-Sadr WM, Lundgren J, Neaton JD, Gordin F, Abrams D, Arduino RC, Babiker A, Burman W, Clumeck N, Cohen CJ, Cohn D, Cooper D, Darbyshire J, Emery S, Fätkenheuer G, Gazzard B, Grund B, Hoy J, Klingman K, Losso M, Markowitz N, Neuhaus J, Phillips A, Rappoport C. CD4 Count–Guided Interruption of Antiretroviral Treatment. N Engl J Med 2006;355(22):2283–96.
  4. Kuller LH, Tracy R, Belloso W, et al. Inflammatory and coagulation biomarkers and mortality in patients with HIV infection. PLoS Med 2008;5(10):e203. Ford ES, Greenwald JH, Richterman AG, et al. Traditional risk factors and D-dimer predict incident cardiovascular disease events in chronic HIV infection. AIDS 2010;24(10):1509–17.
  5. Gupta SK, Mi D, Dubé MP, et al. Pentoxifylline, inflammation, and endothelial function in HIV-infected persons: a randomized, placebo-controlled trial. PLoS One 2013;8(4):e60852. Gupta SK, Johnson RM, Saha C, et al. Improvement in HIV-related endothelial dysfunction using the anti-inflammatory agent salsalate: a pilot study. AIDS 2008;22(5):653–5.
  6. Hsue PY, Hunt PW, Schnell A, et al. Role of viral replication, antiretroviral therapy, and immunodeficiency in HIV-associated atherosclerosis. AIDS 2009;23(9):1059–67.
  7. Torriani FJ, Komarow L, Parker RA, et al. Endothelial function in human immunodeficiency virus-infected antiretroviral-naive subjects before and after starting potent antiretroviral therapy: The ACTG (AIDS Clinical Trials Group) Study 5152s. J Am Coll Cardiol 2008;52(7):569–76. The Strategies for Management of Antiretroviral Therapy (SMART) Study Group. Inferior Clinical Outcome of the CD4 Cell Count–Guided Antiretroviral Treatment Interruption Strategy in the SMART Study: Role of CD4 Cell Counts and HIV RNA Levels during Follow‐up. J Infect Dis 2008;197(8):1145–55.
  8. Lichtenstein KA, Armon C, Buchacz K, et al. Low CD4 T Cell Count Is a R